Announcement on Outline of the Q3 2025 Performance Briefing
Filed with SSE · · 4 pages · Chinese
Summary by 6ix AI
The briefing took place via an online interactive format on a specified date. Company executives discussed financial status, market expansion, and future strategies with investors. The company addressed investor questions regarding market trends and product developments during the session. This filing serves to inform stakeholders about the performance briefing and its outcomes.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Tianjin Tianyao Pharmaceuticals Co., Ltd. on 6ix
Earlier from Tianjin Tianyao Pharmaceuticals
- Announcement on Subsidiary’s Products Being Proposed for Selection in the National Centralized Drug Procurement
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction
- Announcement on the Company's Receipt of the Notice of Approval for Marketing Application of Chemical APIs
- 2025 Semi-annual Report
Later from Tianjin Tianyao Pharmaceuticals
- Announcement on Resolutions of the 22nd Meeting of the 9th Board of Directors
- Announcement on Resolutions of the 23rd Meeting of the 9th Board of Directors
- Announcement on Resignation of Senior Management Member
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Receiving Decision on Administrative Supervision Measures from Tianjin Securities Regulatory Bureau
Follow Tianjin Tianyao Pharmaceuticals into a list and get an email when it puts out news.
Follow Tianjin Tianyao Pharmaceuticals